Page last updated: 2024-09-02
fingolimod hydrochloride and plx4032
fingolimod hydrochloride has been researched along with plx4032 in 2 studies
Compound Research Comparison
Studies (fingolimod hydrochloride) | Trials (fingolimod hydrochloride) | Recent Studies (post-2010) (fingolimod hydrochloride) | Studies (plx4032) | Trials (plx4032) | Recent Studies (post-2010) (plx4032) |
---|---|---|---|---|---|
2,771 | 157 | 2,062 | 1,657 | 103 | 1,587 |
Protein Interaction Comparison
Protein | Taxonomy | fingolimod hydrochloride (IC50) | plx4032 (IC50) |
---|---|---|---|
Chain A, AKAP9-BRAF fusion protein | Homo sapiens (human) | 0.031 | |
RAF proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | 0.182 | |
Serine/threonine-protein kinase A-Raf | Homo sapiens (human) | 0.521 | |
Serine/threonine-protein kinase B-raf | Homo sapiens (human) | 0.0897 | |
Serine/threonine-protein kinase B-raf | Mus musculus (house mouse) | 0.03 | |
Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.36 | |
Dual specificity mitogen-activated protein kinase kinase 2 | Homo sapiens (human) | 1.5 | |
Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | 1.5 | |
Mitogen-activated protein kinase kinase kinase 20 | Homo sapiens (human) | 0.0272 |
Research
Studies (2)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Leiner, P | 1 |
Abe, N; Banno, Y; Kanoh, H; Seishima, M; Takahashi, T | 1 |
Other Studies
2 other study(ies) available for fingolimod hydrochloride and plx4032
Article | Year |
---|---|
[Galenus von Pergamon Prize 2012. Excellent research and innovation].
Topics: Antineoplastic Agents; Awards and Prizes; Drug Approval; Drug Discovery; Drug Industry; Fingolimod Hydrochloride; Germany; Humans; Immunosuppressive Agents; Indoles; Organizational Innovation; Propylene Glycols; Sphingosine; Sulfonamides; Vemurafenib | 2012 |
Synergistic effects of vemurafenib and fingolimod (FTY720) in vemurafenib‑resistant melanoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Fingolimod Hydrochloride; Humans; Melanoma; Proto-Oncogene Proteins c-akt; Signal Transduction; Vemurafenib | 2018 |